Baxter International Inc. (NYSE:BAX), renowned globally for its excellence in injectables, anesthesia, and drug compounding, has unveiled a significant expansion of its Pharmaceuticals portfolio with the introduction of five new injectable products in the United States.
Alok Sonig, Executive Vice President and Group President of Pharmaceuticals at Baxter, highlighted the company’s commitment to delivering innovative solutions to address critical patient needs in key therapeutic areas such as anti-infective and anti-hypotensive medications. He expressed pride in the addition of these vital options to Baxter’s offerings and emphasized the company’s ongoing dedication to introducing new advancements to the market.
The newly launched products within Baxter’s Pharmaceuticals portfolio in the U.S. encompass a range of essential treatments. Notable introductions include:
- Norepinephrine Bitartrate in 5% Dextrose Injection, now available in a new 16 mg/250 mL strength. This product is indicated for raising blood pressure in adult patients experiencing severe, acute hypotension. Baxter’s offering stands out as the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, providing flexibility with strengths ranging from 4 mg/250 mL to 16 mg/250 mL.
- Vasopressin in 0.9% Sodium Chloride Injection, the initial FDA-approved ready-to-use Vasopressin presented in a flexible container. Utilizing Baxter’s proprietary sterile, closed system container, this product simplifies administration and reduces the risk of contamination. It is indicated for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Available strengths include 20 units/100 mL and 40 units/100 mL.
- Vancomycin Injection, USP in 5% Dextrose, now offered in new strengths of 1.25 g/250 mL and 1.5 g/300 mL. These additions mark Baxter’s introduction of frozen ready-to-use options in 250 mL and 300 mL volumes, catering to the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. The product lineup includes strengths ranging from 500 mg/100 mL to 1.5 g/300 mL.
- Ropivacaine Hydrochloride Injection, USP, presented in a convenient, ready-to-use, single-dose infusion bag. Indicated for use in adults for local or regional anesthesia during surgery and acute pain management, Baxter offers strengths of 200 mg/100 mL and 400 mg/200 mL.
- Regadenoson Injection pre-filled syringe, a coronary vasodilator commonly employed in pharmacologic stress testing, now available in a 0.4 mg/5 mL strength.
These product launches aim to streamline healthcare provider operations by providing ready-to-use formats of standard concentrations of commonly prescribed drugs. By eliminating the need for manual compounding processes, these products reduce the risk of contamination and potential errors, thereby enhancing patient safety.
The newly introduced products are now accessible for utilization in the United States, marking a significant step forward in Baxter’s mission to deliver impactful pharmaceutical solutions to healthcare providers and patients alike.
